摘要
目的:研究丙型肝炎患者IL28B基因相关的rs12979860基因型和HCV基因型对聚乙二醇干扰素α和利巴韦林联合抗病毒治疗疗效的影响.方法:对干扰素α联合利巴韦林治疗后获得持续病毒学应答(SVR)和无应答(NR)的各30例丙型肝炎患者的血液样品样进行检测,采用PCR反向斑点杂交法进行HCV基因分型,采用聚合酶链-连接酶检测反应进行患者IL28B相关的单核苷酸多态性(SNP)rs12979860基因分型.结果:抗病毒治疗后SVR的30例丙型肝炎患者中,HCV基因型为1b的有3例,非HCV-1b基因型的有27例,rs12979860基因型为C/C型(保护性基因型)的有29例,为T/C型(非保护性基因型)的有1例;抗病毒治疗后NR的30例丙型肝炎患者中,HCV基因型为1b的有12例,为非HCV-1b基因型的有18例,rs12979860基因型为C/C型的有20例,为T/C型的有10例.HCV-1b和非HCV-1b感染者在获得SVR率之间的差异有显著性(P<0.05),获得早期病毒学应答的患者都是保护性SNP基因型携带者,保护性和非保护SNP基因型携带者获得SVR率之间的差异有显著性(P<0.05).结论:HCV-1b型病毒感染者治疗后获得SVR的几率低于非HCV-1b型的患者,rs12979860为C/C基因型的患者治疗后获得SVR的几率高于T/C基因型的患者;将HCV的病毒基因型与宿主rs12979860基因型检测相结合,可作为丙型肝炎患者干扰素联合利巴韦林治疗疗效预测评价的重要指标.
AIM： To explore the association of IL28B single nucleotide polymorphism （SNP） and hepatitis C virus （HCV） genotypes with response to pegylated interferon-α and ribavirin therapy in patients with chronic hepatitis C. METHODS： Blood samples from patients who were sustained virological responders （SVR） or non-responders （NR） after pegylated interferon-α and ribavirin therapy for chronic hepatitis C, were collected and used for genotyping of HCV and IL28B SNP rs12979860. RESULTS： Of 30 patients with sustained virological response, 3 were infected with HCV-1b, 27 with non-HCV-1b; 29 had a C/C genotype of rs12979860, 1 had a T/C genotype. Of 30 patients with non-response, 12 were infected with HCV-lb, 18 with non-HCV-1b; 20 had a C/C genotype of rs12979860, 10 had a T/C genotype. Patients who were infected with non-HCV-1b had better SVR rate than those with HCV lb infection. Patients who had a C/C genotype of rs12979860 had better SVR rate than those with a T/C genotype.CONCLUSION： IL28B SNP and HCV genotypes could be predictive of response to antiviral therapy in patients with chronic hepatitis C.
出处
《世界华人消化杂志》
CAS
北大核心
2011年第22期2372-2375,共4页
World Chinese Journal of Digestology
基金
昆明学院引进博士专项基金资助项目
No.昆明学院YTL11005~~
